Decreased glucagon levels and decreased insulin secretion after sitagliptin versus mitiglinide administration with similar glycemic levels following an oral glucose load: a randomized crossover pharmaceutical mechanistic study

[1]  Soo-Youn Lee,et al.  Additive Postprandial Glucose-Lowering Effects of Mitiglinide and Sitagliptin in Patients with Type 2 Diabetes Mellitus , 2013, Advances in Therapy.

[2]  J. Kirwan,et al.  Pancreatic β-cell function increases in a linear dose-response manner following exercise training in adults with prediabetes. , 2013, American journal of physiology. Endocrinology and metabolism.

[3]  M. Fujiwara,et al.  Comparison between sitagliptin and nateglinide on postprandial lipid levels: The STANDARD study. , 2013, World journal of diabetes.

[4]  G. Chrysant,et al.  Clinical implications of cardiovascular preventing pleiotropic effects of dipeptidyl peptidase-4 inhibitors. , 2012, The American journal of cardiology.

[5]  Y. Eto,et al.  Nateglinide stimulates glucagon-like peptide-1 release by human intestinal L cells via a K(ATP) channel-independent mechanism. , 2011, Biological & pharmaceutical bulletin.

[6]  M. Shibasaki,et al.  Effects of antidiabetic drugs in high-fat diet and streptozotocin-nicotinamide-induced type 2 diabetic mice. , 2011, European journal of pharmacology.

[7]  J. Holst,et al.  Effects of short-term therapy with glibenclamide and repaglinide on incretin hormones and oxidative damage associated with postprandial hyperglycaemia in people with type 2 diabetes mellitus. , 2011, Diabetes research and clinical practice.

[8]  M. Laakso,et al.  Effect of nateglinide on the incidence of diabetes and cardiovascular events. , 2010, The New England journal of medicine.

[9]  J. Lindsay,et al.  Insulinotropic actions of nateglinide in type 2 diabetic patients and effects on dipeptidyl peptidase-IV activity and glucose-dependent insulinotropic polypeptide degradation. , 2009, European journal of endocrinology.

[10]  M. Matsuda,et al.  The relationship between fasting hyperglycemia and insulin secretion in subjects with normal or impaired glucose tolerance. , 2008, American journal of physiology. Endocrinology and metabolism.

[11]  R. DeFronzo,et al.  Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study. , 2008, Current medical research and opinion.

[12]  Y. Tamura,et al.  Nateglinide Reduces Carotid Intima-Media Thickening in Type 2 Diabetic Patients Under Good Glycemic Control , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[13]  N. Irwin,et al.  Effects of antidiabetic drugs on dipeptidyl peptidase IV activity: nateglinide is an inhibitor of DPP IV and augments the antidiabetic activity of glucagon-like peptide-1. , 2007, European journal of pharmacology.

[14]  J. Holst,et al.  Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes. , 2006, The Journal of clinical endocrinology and metabolism.

[15]  R. Turner,et al.  Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man , 1985, Diabetologia.

[16]  Markolf Hanefeld,et al.  Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. , 2003, JAMA.

[17]  J. Holst,et al.  Gastric inhibitory polypeptide (GIP) dose-dependently stimulates glucagon secretion in healthy human subjects at euglycaemia , 2003, Diabetologia.

[18]  J. Holst,et al.  Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers. , 2002, The Journal of clinical endocrinology and metabolism.

[19]  M. Matsuda,et al.  Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. , 1999, Diabetes care.

[20]  R. Hovorka,et al.  ISEC: a program to calculate insulin secretion. , 1996, Computer methods and programs in biomedicine.

[21]  Y. Ajisawa,et al.  Effect of a non‐sulphonylurea hypoglycaemic agent, KAD‐1229 on hormone secretion in the isolated perfused pancreas of the rat , 1996, British journal of pharmacology.